Kindred Biosciences — Investor Presentation (May 2018)
39 slides from Kindred Biosciences's investor presentation, May 24, 2018
Slide 1: KindredBio: Best Medicines for Our Best Friends
(Kindred Bio Best Medicines for Our Best Fri
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains forward- looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward- looking stat
Slide 3: We Spend Generously on Pets
WE SPEND GENEROUSLY ON PETS $69.4 $ 1.5 $700 BILLION BILLION MILLION We spend $69.4 We spend $1.5 We spend $700 billion a year on billion a year on million a year on pets knee surgeries for Valentine’s Day dogs presents for pets 3
Slide 4: Because Pets Are Family
BECAUSE PETS ARE FAMILY 67 37 71 PERCENT PERCENT PERCENT 67% of pet 37% of pet 71% of pets sleep parents would parents would in bed with their give up their give up their pet parents vacation to pay cellphone to pay for pet emergency for pet emergency 4
Slide 5: KindredBio's Strategy: Repurpose Human Drugs for Pets
KINDREDBIO’S STRATEGY: REPURPOSE HUMAN DRUGS FOR PETS Pursue molecules already $5-8M to develop each known to work drug in 3-6 years Reduce technical risk Reduce financial risk Reduce timelines Portfolio approach 5
Slide 6: Deep Product Pipeline
DEEP PRODUCT PIPELINE Laboratory Field Pivotal Approval Molecule Indication Preclinical Pilot Studies Pilot Studies Study Management of Mirataz™ Approved weight loss in cats Rolling NADA Zimeta™ Injection Control of fever in horses Filed Positive Pivotal Zimeta™ Oral Control of fever in horses Study
Slide 7: Deep Product Pipeline: Other Products in Development
DEEP PRODUCT PIPELINE OTHER PRODUCTS IN DEVELOPMENT Laboratory Field Pivotal Approval Molecule Indication Preclinical Pilot Studies Pilot Studies Study KIND-014 Equine gastric ulcers Metabolic syndrome KIND-015 in horses Anti-TNF Antibody Sick newborn foals Inflammatory bowel disease Anti-TNF Antibo
Slide 8: Expected approvals and market size versus development cost
We expect two approvals this year and then an average of two approvals per year thereafter Market sizes are 10 times smaller than human markets but the cost of development is 100 times lower 8
Slide 9: Veterinary Market Is Growing Rapidly
VETERINARY MARKET IS GROWING RAPIDLY 68% 23% The veterinary care Animal health stocks market grew 68% have risen 23% in the from 2007 to 2017 previous year 9
Slide 10: There Is a High Willingness to Pay
THERE IS A HIGH WILLINGNESS TO PAY… $11,000 $10,000 $10,200.15 $10,329.99 A recent study found that, on average, pet $9,000 owners who have both dogs and cats $8,000 would spend over $10,000 to $7,000 save one of their pets from a life-threatening $6,000 v illness or disease $5,000 $4,000 $3,000 $2,
Slide 11: There Is Low Generic Penetration
THERE IS LOW GENERIC PENETRATION Generic Dispensing Rates There are very few generic companies, and no automatic substitution at the pharmacy 81% Human Many products reach peak sales several years after patent expiration 7% Companion There is no biosimilar pathway Animal 11
Slide 12: Mirataz (mirtazapine transdermal ointment)
MIRATAZ™ (mirtazapine transdermal ointment)
Slide 13: Mirataz now available
Mirataz™(mirtazapine transdermal ointment) now available The first and only FDA-approved transdermal medication for the management of weight loss in cats Mirataz is classified pharmacologically as a weight-gain drug1 13 1.. Freedom of Information Summary, Original New Animal Drug Application, NADA 1
Slide 14: Mirataz Opportunity
MIRATAZ™ OPPORTUNITY 9 million cats are diagnosed with unintended weight loss each year Weight loss can lead to liver failure which can be fatal 3 million cats are currently treated for unintended weight loss each year 14
Slide 15: Mirataz Opportunity
MIRATAZ™ OPPORTUNITY 49% of veterinarians report that ease of administering the medication and/or client medication compliance is a primary factor in selecting a medication for feline weight loss 15
Slide 16: Opportunity
OPPORTUNITY 71% of veterinarians use mirtazapine and the majority say they would switch to the transdermal gel formulation 59% 34% 7% 59% of 34% of Only 7% of veterinarians would veterinarians would veterinarians would replace most or all replace some of the not replace any mirtazapine mirtazapine m
Slide 17: The first and only medication for weight loss in cats
The first and only medication for: ‘weight loss in cats “ANOTHER PILL? GIVE IT TO THE DOG.
Slide 18: Zimeta (dipyrone injection)
ZIMETA™ (dipyrone injection)
Slide 19: Zimeta IV Pivotal Field Study Results
ZIMETA™ IV PIVOTAL FIELD STUDY RESULTS 100.0 P<0.0001 90.0 80.0 76.8 Randomized, double-blind, placebo- controlled 70.0 60.0 Primary endpoint: improvement or resolution 50.0 v of fever 40.0 NADA filed, approval expected this year Success Rate (%) 30.0 20.0 19.4 10.0 0.0 Placebo Zimeta IV N=31 N=99 1
Slide 20: Zimeta Oral Pivotal Field Study Results
ZIMETA™ ORAL PIVOTAL FIELD STUDY RESULTS 100.0 P=0.0026 90.0 78.4 80.0 Randomized, double-blind, placebo- controlled 70.0 60.0 Primary endpoint: improvement or resolution 50.0 v of fever 40.0 Success Rate (%) 30.0 20.0 17.6 10.0 0.0 Placebo Zimeta Oral N=34 N=102 20
Slide 21: Zimeta Opportunity
ZIMETA™ OPPORTUNITY 95% 83% 95% believe that 83% would use Zimeta is a good fit Zimeta in the for their practice first year 21
Slide 22: Commercialization
COMMERCIALIZATION
Slide 23: Equine and Companion Animal Commercialization
EQUINE COMMERCIALIZATION Commercialize with 3-5 person direct sales force, in conjunction with distributors COMPANION ANIMAL COMMERCIALIZATION Commercialize with 20-25 person direct sales force, in conjunction with distributors 23
Slide 24: World-Class Commercial Team
WORLD-CLASS COMMERCIAL TEAM 15.7 > 50 TOP YEARS LAUNCHES COMPANIES Sales force has Team members The team comes average have launched from top experience of over 50 products veterinary 15.7 years companies 24 24
Slide 25: Biologics
BIOLOGICS
Slide 26: Biologics
BIOLOGICS Industry leading biologic programs State-of-the-art biologics manufacturing plant Highly experienced biologics team New technologies, including KIND-bodies 26
Slide 27: epoCat Feline Erythropoietin
epoCat™ FELINE ERYTHROPOIETIN Recombinant long-acting feline erythropoietin for non-regenerative anemia in cats Half of elderly cats develop kidney disease which can cause anemia 27
Slide 28: epoCat
epoCat™ Initial laboratory study has been completed and the results were positive, as evidenced by increase in new red blood cells Pilot field efficacy study is under way 28
Slide 29: Key Focus Area: Atopic Dermatitis
KEY FOCUS AREA ATOPIC DERMATITIS Canine atopic dermatitis, an allergic skin disease, is a >$500M a year market KindredBio has an industry-leading portfolio of atopic dermatitis candidates 29
Slide 30: Canine IL31 Antibody
CANINE IL31 ANTIBODY Second generation antibody that blocks IL31, a mediator of itching Fully caninized and high affinity Successfully completed pilot safety study and pilot efficacy study underway 30
Slide 31: Other Candidates: Atopic Dermatitis
OTHER CANDIDATES ATOPIC DERMATITIS Initial pilots studies of IL17 antibody, and IL13/IL4 SINK have also been completed and the molecules were well tolerated KindredBio has multiple other preclinical candidates for atopic dermatitis 31
Slide 32: Corporate Info
CORPORATE INFO
Slide 33: Select Summary Financials
SELECT SUMMARY FINANCIALS March 31, 2018 Operating expenses Quarter Year Research and Development $5.3 $5.3 General and Administrative $4.9 $4.9 Total cash operating expenses $8.7 $8.7 (excluding stock-based compensation) Total operating expenses $10.2 $10.2 (including stock-based compensation) Tota
Slide 34: Capital Structure and Stock History
CAPITAL STRUCTURE AND STOCK HISTORY Shares outstanding1 28.2M Options2 5.6M Market Cap3 US$273.6M Analyst Coverage Kevin DeGeeter • Ladenburg Thalmann • [email protected] Andrew D'Silva • B. Riley FBR • [email protected] Swayampakula Ramakanth • H.C. Wainwright & Co. • sramakanth@hcwresear
Slide 35: News Flow
NEWS FLOW Zimeta IV approval in 2018 Pilot efficacy results from equine ulcer study in 2018 Pilot efficacy results from IL31 antibody study in 2018 Pilot efficacy results from epoCat study in early 2019 Pilot efficacy results from IL4/IL13 study in early 2019
Slide 36: Summary
SUMMARY
Slide 37: Summary
SUMMARY KindredBio develops innovative therapies for companion animals by leveraging validated human drugs. The markets are ten times smaller than human markets but the cost of development is a hundred times lower. KindredBio expects to launch average of two drugs per year.
Slide 38: Slide 38
Slide 39: Sources
SOURCES SLIDE 3 : 2017-2018 APPA National Pet Owners Survey Journal of the American Veterinary Medical Association, November 15, 2005, Vol. 227, No. 10, Pages 1604-1607, https://doi.org/10.2460/javma.2005.227.1604 Valentine’s Day Gift Spend: National Retail Foundation—http://consumerist.com/2015/01/
Kindred Biosciences — Investor Presentation (May 2018) on 6ix